论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Lupattelli A, Twigg MJ, Zagorodnikova K, Moretti ME, Drozd M, Panchaud A, Rieutord A, Gjergja Juraski R, Odalovic M, Kennedy D, Rudolf G, Juch H, Nordeng H
Received 8 November 2017
Accepted for publication 16 February 2018
Published 6 June 2018 Volume 2018:10 Pages 655—669
DOI https://doi.org/10.2147/CLEP.S156210
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 3
Editor who approved publication: Professor Irene Petersen
Purpose: This study aimed at exploring the prevalence of self-reported antenatal
and postnatal depressive symptoms by severity across multiple countries and the
association between antidepressant treatment in pregnancy and postnatal symptom
severity.
Materials and methods: This was a multinational web-based study conducted
across 12 European countries (n=8069). Uniform data collection was ensured via
an electronic questionnaire. Pregnant women at any gestational week and mothers
of children with <1 year of age could participate. We used the Edinburgh
Postnatal Depression Scale (EPDS) to measure the prevalence of antenatal and
postnatal depressive symptoms according to severity, which were corrected by
survey weight adjustment (descriptive analysis). Within mothers with a psychiatric
disorder (n=173), we estimated the association between antidepressant treatment
in pregnancy and postnatal depressive symptom severity, as standardized EPDS
mean scores, via the inverse probability of treatment weight (association
analysis).
Results: In the descriptive analysis (n=8069), the period
prevalence of moderate-to-very severe depressive symptoms was higher in the
western and eastern regions relative to the northern region, both in the
antenatal period (6.8%–7.5% vs 4.3%) and in the postnatal period (7.6% vs
4.7%). One in two mothers with psychiatric disorders used an antidepressant in
pregnancy (86 of 173). In the association analysis, women medicated at any time
during pregnancy (adjusted β=−0.34, 95% confidence interval [CI] =−0.66, −0.02)
had a significant postnatal symptom severity reduction compared with the
nonmedicated counterpart. This effect was larger (β=−0.74, 95% CI =−1.24,
−0.24) when the analysis was restricted to mothers within 6 months after
childbirth.
Conclusion: The prevalence of self-reported antenatal and
postnatal depressive symptoms differs across European countries. Among women
with psychiatric disorders, those who had been on treatment with
antidepressants during pregnancy were less likely to report postnatal depressive
symptoms, particularly within the 6-month period after childbirth, compared
with the nonmedicated counterpart.
Keywords: antidepressants,
pharmacotherapy, pregnancy and postpartum, depression, anxiety, web-based
摘要视频链接:Perinatal depressive symptoms
and antidepressants